文献速递支持与姑息治疗骨软组织肉瘤与黑色素瘤

免疫介导毒性所致急诊就诊的患者与治疗特征

Patient and treatment characteristics of emergency presentations due to immune-mediated toxicities.
PubMed 文献 · Eur J Cancer · 2022-02-14

本研究回顾性分析单中心2018年5月至2020年3月接受免疫检查点抑制剂(ICI)治疗患者的全部急诊就诊记录。1165例接受ICI治疗的患者共发生597次急诊就诊(涉及370例患者),其中191/597次(32%)由免疫介导毒性所致;黑色素瘤、联合免疫治疗及既往≥2级免疫介导毒性在该组中常见。

要点

  • 1165例ICI治疗患者中370例发生597次急诊就诊,191/597次(32%)为免疫介导毒性所致。
  • 免疫介导毒性组最常见肿瘤为黑色素瘤(53%)和肺癌(22%),最常见方案为伊匹木单抗+纳武利尤单抗联合免疫治疗(42%)。
  • 该组中75/191(39%)有既往≥2级免疫介导毒性,29%需二线免疫抑制治疗。

核心结论

  • 超过四分之一接受ICI治疗的患者发生急诊就诊,其中免疫介导毒性占32%。
  • 黑色素瘤诊断、联合免疫治疗及既往≥2级免疫介导毒性在免疫介导毒性患者中常见。
  • 这些数据有助于更好地识别可能需要住院的患者,并为急性肿瘤服务的前瞻规划提供依据。

研究设计与样本

  • 本研究为单中心回顾性研究,复习2018年5月至2020年3月接受ICI治疗患者的全部急诊就诊记录。
  • 共1165例患者接受ICI治疗,370例患者发生597次急诊就诊。
  • 研究目的是描述和量化患者与治疗特征、毒性类型及结局。

主要发现

  • 597次急诊就诊中191次(32%)由免疫介导毒性所致,中位年龄64岁,127/191(67%)为男性。
  • 免疫介导毒性组最常见肿瘤类型为黑色素瘤(53%)和肺癌(22%)。
  • 最常见ICI为伊匹木单抗+纳武利尤单抗联合免疫治疗(42%),其次为帕博利珠单抗单药(21%)和纳武利尤单抗单药(20%)。
  • 中位接受周期数为3(范围1-54),75/191(39%)有既往≥2级免疫介导毒性。
  • 29%患者需要二线免疫抑制治疗,中位住院时间为4天;急诊就诊数量上升反映ICI总体使用增加。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The prevalence of immune-mediated toxicities from immune checkpoint inhibitors (ICIs) is well described. However, the characteristics and treatment patterns for patients with emergency presentations owing to immune-mediated toxicity are less well known. MATERIALS AND METHODS: This study reviews all emergency presentations in patients treated with ICI at a single centre between May 2018 and March 2020. The aims were to describe and quantify patient and treatment characteristics, toxicity type and outcomes. RESULTS: 1165 patients were treated with ICI, and there were 597 emergency presentations in 370 patients. Of these, 191/597 (32%) were owing to an immune-mediated toxicity, median age was 64 years, and 127/191 (67%) were men. The most common tumour types were melanoma (53%) and lung cancer (22%), and the most common ICI received was ipilimumab + nivolumab combination immunotherapy (42%), followed by pembrolizumab monotherapy (21%) and nivolumab monotherapy (20%). The median number of cycles received was three (range 1-54), and 75/191 (39%) had previous ≥ grade 2 immune-mediated toxicity. 29% patients required second-line immunosuppression. The median time in the hospital was four days. There was a rising number of emergency presentations reflecting overall increasing use of ICI. CONCLUSIONS: Over a quarter of patients treated with ICI had an emergency presentation, and immune-mediated toxicity accounted for 32% of these. A diagnosis of melanoma, treatment with combination immunotherapy and previous ≥ grade 2 immune-mediated toxicity were common in patients with immune-mediated toxicity. These data allow better identification of patients likely to require admission and forward planning for acute oncology services.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Nahm SH, Heywood R, Callaghan S, et al. Patient and treatment characteristics of emergency presentations due to immune-mediated toxicities. Eur J Cancer. 2022. PMID: 35176613. doi:10.1016/j.ejca.2021.12.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。